Hi Archit, Those numbers come from GenWorks, of course. They claim to have done between ~Rs 420 crore and ~Rs 500 crore of sales across all products (they do sell some non-GE products, where it's not competitive). At a 15% CAGR (the non-conservative estimate), they estimate Rs 800 crore of sales (rounded up from ~Rs 760 crore) across the *entire product porfolio*. A 10% CAGR would place them at Rs 655 crore. Of course, future numbers are always claims.

Gayathri Vaidyanathan

Hi Karthik, Her theory was that there's something nefarious about Tierra (the link out takes you to her letter, if you're interested). As to what happened to it, the CCI approved the sale to Tierra and the Bayer-Monsanto merger took place.

Gayathri Vaidyanathan

Read once more? :)

Gayathri Vaidyanathan

Hi Kaushik, the pollution hotspot extends all the way from Pakistan, through the northern belt of India and into Bangladesh. Unlike humans, pollution knows no bounds.

Gayathri Vaidyanathan

yes, hospitals could have differential pricing for entire package of medical procedure that includes consumables

Gayathri Vaidyanathan

Hi Archit, thank you. You could say inefficient operations - returns don't match their high investments due to oversupply of hospital beds among corporate hospitals

Gayathri Vaidyanathan

Hi Shailesh, thank you for reading. From my colleague Ruhi: TPAs are hired by the insurance companies. By definition they are third parties and administrators. It is up to insurance companies to standardise rates. And they have. Hospitals usually charge non-standardised prices to people who are paying out of pocket.

Gayathri Vaidyanathan

Agree, and we will definitely take it into consideration. Thank you!

Gayathri Vaidyanathan

Hi Viswanathan, thanks for reading. What you suggest would be an interesting article -- but not the point of this piece, which examines medical device suppliers and how they do business. Furthermore, as I point out in the article, hospitals do need the margins given their high investments.

Gayathri Vaidyanathan

Hi Ramprasad, It's not that the distributor is making a loss, and your second guess is correct. In some cases, hospitals procure directly from the manufacturer and they have greater negotiating power if they are a large chain like Fortis, so their wholesale price can be lower than the price to distributor.

Gayathri Vaidyanathan

Abbott has pulled out other advanced stents because of the price cap, and that indeed is the prevailing narrative. But there's more to the Absorb pullout that just that. Abbott removed it from the market all across the world after many doctors stopped using it because of safety concerns.

Gayathri Vaidyanathan

Hi Prateek, the Rs 3000 is a monthly revenue figure. This is different from the Rs 25,000 is the *conservative* LTV of a customer that Cure.fit is seeing currently (so, an avg customer who buys a discounted annual pack + a few other things like Eat.fit meals). Regarding your second point, I'm sorry, that should be *eats*, not orders. Thanks for catching that.

Gayathri Vaidyanathan